[go: up one dir, main page]

MX9703944A - Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis. - Google Patents

Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.

Info

Publication number
MX9703944A
MX9703944A MX9703944A MX9703944A MX9703944A MX 9703944 A MX9703944 A MX 9703944A MX 9703944 A MX9703944 A MX 9703944A MX 9703944 A MX9703944 A MX 9703944A MX 9703944 A MX9703944 A MX 9703944A
Authority
MX
Mexico
Prior art keywords
triaryl
osteoporosis
prevention
treatment
ethylene derivatives
Prior art date
Application number
MX9703944A
Other languages
English (en)
Inventor
Alan J Bitonti
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/531,885 external-priority patent/US5691384A/en
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of MX9703944A publication Critical patent/MX9703944A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a un método para usar derivados de triaril-etileno en el tratamiento o prevencion de pérdida de tejido oseo u osteoporosis.
MX9703944A 1994-11-29 1995-10-27 Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis. MX9703944A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34611194A 1994-11-29 1994-11-29
US08/531,885 US5691384A (en) 1994-11-29 1995-10-11 Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
PCT/US1995/013873 WO1996016646A1 (en) 1994-11-29 1995-10-27 Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis

Publications (1)

Publication Number Publication Date
MX9703944A true MX9703944A (es) 1998-05-31

Family

ID=26994698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9703944A MX9703944A (es) 1994-11-29 1995-10-27 Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.

Country Status (12)

Country Link
US (1) US5693674A (es)
EP (1) EP0794771A1 (es)
JP (1) JPH10509962A (es)
CN (1) CN1167437A (es)
AU (1) AU707290B2 (es)
CA (1) CA2206422A1 (es)
FI (1) FI972235A7 (es)
HU (1) HUT77603A (es)
IL (1) IL116142A0 (es)
MX (1) MX9703944A (es)
NO (1) NO972426L (es)
WO (1) WO1996016646A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
JP5123935B2 (ja) * 2006-05-22 2013-01-23 ホルモス メディカル リミテッド 選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
ES2590262T3 (es) * 2007-02-14 2016-11-21 Hormos Medical Ltd. Método para la preparación de derivados de trifenilbuteno con valor terapéutico
BRPI0913673A2 (pt) 2008-07-02 2015-10-13 British Columbia Cancer Agency uso de um composto, composição farmacêutica, e, método para modular a atividade do receptor de andrógeno
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
JP6884100B2 (ja) * 2015-01-13 2021-06-09 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ がんの画像化及び治療用のヘテロ環式化合物ならびにそれらの使用方法
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
MX2021004427A (es) 2018-10-18 2021-11-12 Univ British Columbia Moduladores del receptor de andrógenos y métodos para su uso.
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
JP2023522040A (ja) 2020-04-17 2023-05-26 エッサ ファーマ，インコーポレイテッド Ｎ末端ドメインアンドロゲン受容体阻害剤の固体形態およびその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
GB1013907A (en) * 1962-09-13 1965-12-22 Ici Ltd Alkene derivatives
US3247252A (en) * 1962-11-14 1966-04-19 Richardson Merrell Inc Beta-dialkylaminoethylamino-triphenylethanols, -ethanes, and -ethenes
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
GB1128379A (en) * 1966-06-20 1968-09-25 Ici Ltd Novel alkene derivatives, process for the preparation thereof and compositions containing the same
US4001229A (en) * 1974-04-04 1977-01-04 Mead Johnson & Company Alkanesulfonamido triphenylethylenes
DE2860900D1 (en) * 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4970237A (en) * 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
JPH06312930A (ja) * 1993-04-30 1994-11-08 Kuraray Co Ltd 骨粗鬆症治療剤
US5525633A (en) * 1993-09-24 1996-06-11 Merrell Dow Pharmaceuticals Inc. Triaryl-ethylene derivatives
ZA956029B (en) * 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss

Also Published As

Publication number Publication date
CA2206422A1 (en) 1996-06-06
FI972235A0 (fi) 1997-05-27
WO1996016646A1 (en) 1996-06-06
NO972426L (no) 1997-07-29
NO972426D0 (no) 1997-05-28
US5693674A (en) 1997-12-02
EP0794771A1 (en) 1997-09-17
FI972235L (fi) 1997-05-27
JPH10509962A (ja) 1998-09-29
FI972235A7 (fi) 1997-05-27
IL116142A0 (en) 1996-01-31
AU4196796A (en) 1996-06-19
CN1167437A (zh) 1997-12-10
AU707290B2 (en) 1999-07-08
HUT77603A (hu) 1998-06-29

Similar Documents

Publication Publication Date Title
MX9703944A (es) Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
ES2135083T3 (es) Trifeniletilenos para la prevencion y el tratamiento de la osteoporosis.
NO972043D0 (no) Tienopyridin eller tienopyrimidinderivater og deres anvendelse
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
ECSP034441A (es) Tratamiento de depositos de sulfuro de hierro
IL132159A0 (en) Plant extracts for the treatment of increased bone resorption
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
NO965563D0 (no) Behandling og profylakse av osteoporese
NO962752D0 (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
BG102797A (en) The carboznhydrase inhibitor application for the treatment of the maculate oedema
BG105275A (en) Tan-1057 derivatives
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
BG102667A (en) Diosgenine-containing composition
HU9601496D0 (en) Use of dimeticone for treating aphthae and stomatitis
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
BR9709264A (pt) Processo para produzir e composto
DK0968174T3 (da) Optisk aktiv 2-aminotetralin, fremgangsmåde til dets fremstilling og farmaceutiske præparater indeholdende selv samme, effektiv til forebyggelse og behandling af septisk chok
ES2180643T3 (es) Procedimiento para tratar la disfuncion cognitiva.
BR0112460A (pt) Método para tratamento de sépsis